Pulling SEC filings + quote and writing the call…

Cartesian Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.89 EPS, $137K rev
Last earnings -3.9% on 2026-04-30
Conservative balance sheet (liabilities/equity -3.35x); but revenue fell -99.0% YoY.
Cartesian Therapeutics, Inc. shows $400K in FY2025 revenue (-99.0% YoY), a -32575.5% net margin.
Sources: SEC EDGAR (CIK 0001453687, latest 10-Q filed 2026-04-30) · EODHD · as of 6/26/2026, 7:09:42 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $85.1M | $111M | $26.0M | $38.3M | $400K |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.60M | $14.5M | -$86.4M | -$43.9M | -$143M |
| Net income | -$25.7M | $35.4M | -$220M | -$77.4M | -$130M |
| Diluted EPS | -$0.22 | $0.10 | -$49.76 | -$4.49 | -$5.02 |
| Net margin | -30.2% | 31.9% | -844.9% | -202.3% | -32575.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1049 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-04-02 | Hoge Elizabeth 10% owner | Exercise | 758K | |
| 2026-04-02 | Kalayoglu Murat 10% owner | Exercise | 758K | |
| 2026-03-13 | Singer Michael Director | Gift | 6.55K | |
| 2026-01-06 | Brunn Carsten President and CEO | Sell | 23.8K @ $6.82 | $162K |
| 2026-01-06 | Miljkovic Milos Chief Medical Officer | Sell | 3.57K @ $6.82 | $24.4K |
| 2026-01-06 | Davis Blaine Chief Financial Officer | Sell | 10.6K @ $6.82 | $72.2K |
| 2026-01-02 | DeSilva Nishan M Director | Award | 2.60K | |
| 2026-01-02 | Brunn Carsten President and CEO | Award | 143K |